Alan Nurden: One of The Best Articles That I Have Read in 2025
Alan Nurden, Emeritus Research Director at CNRS, shared on LinkedIn:
”One of the best articles that I have read in 2025.
The wide-ranging pathophysiology of RUNX1 mutations is clearly illustrated through a series of case reports where families were gentotyped using a NGS-based sequencing panel.
The association of platelet function defects, thrombocytopenia and malignancy risk is highlighted case by case in a thoroughly professional manner.
Highly recommended.”
Read the full article in Frontiers.
Article: RUNX1-FPDMM in families with mild thrombocytopenia and platelet function anomalies: a case series
Authors: Hannah Glonnegger, Doris Boeckelmann, Rebekka Wiedenhöfer, Wolf-Achim Hassenpflug, Tim Ripperger, Dirk Lebrecht, Ralf Knöfler, Oliver Tiebel, Udo Koehler, Claudia Wehr, Harry Sirb, Monika Sparber-Sauer, Katrin Reinsberger, Ayami Yoshimi, Brigitte Strahm, Barbara Zieger
Stay updated on all scientific advances with Hemostasis Today.
-
Feb 23, 2026, 14:45Stacey McGeown: Rare Disease Awareness Day at QUB Marks the Start of Rare Disease Month
-
Feb 23, 2026, 13:53Rare Diseases, Plasma-Derived Medicines and the Elephant in the Room – Part 1
-
Feb 23, 2026, 13:02Deepak Yadav: What 2025 Evidence Tells Us About Stroke Care
-
Feb 23, 2026, 12:55Radoslaw Kaczmarek: Will AAV Gene Therapy for Hemophilia Trigger Tumorigenesis?
-
Feb 23, 2026, 12:46Heghine Khachatryan: More Granular Risk Stratification Framework for PE from The New 2026 AHA/ACC Guideline
-
Feb 23, 2026, 12:37Reza Shojaei: EU’s Critical Medicines Act and Plasma Resilience
-
Feb 23, 2026, 12:32Anirban Sen Gupta: Emily Mihalko Highlights PlateChek at MTEC
-
Feb 23, 2026, 12:25Ryan Williams: Excellent Highlights on The Heterogeneity of PRP Preparation
-
Feb 23, 2026, 12:10Peter Libby: hsCRP May Select Patients Who Can Benefit From Statins or Anti-inflammatory Therapy